Tests a radiotracer scan for detecting soft tissue sarcoma
Tests a radioactive tracer PET/CT scan to image soft tissue sarcoma in adults.
Plain-language title generated from the registry record
Registry title: 68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas
Key facts
- Where
- Columbus, United StatesSee the site
Where in United States
- Ohio State University Comprehensive Cancer CenterColumbus, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ohio State University Comprehensive Cancer Center
- Trial code
- NCT06500065
- Record updated
- 2 February 2026
- Original description
This trial studies how well 68Ga-DOTATATE digital PET/CT work in diagnosing soft tissue sarcoma. 68Ga-DOTATATE is a radiotracer that may improve image quality of PET imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-DOTATATE. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. 68Ga-DOTATATE digital PET/CT may work better in imaging patients with soft tissue sarcomas.Read full original descriptionShow less
Clinical Feasibility and Potential Clinical Benefit of 68Ga-DOTATATE PET/CT Assessment of Soft Tissue Sarcomas for Potential Peptide Receptor Radionuclide Therapy
This trial studies how well 68Ga-DOTATATE digital PET/CT work in diagnosing soft tissue sarcoma. 68Ga-DOTATATE is a radiotracer that may improve image quality of PET imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-DOTATATE. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. 68Ga-DOTATATE digital PET/CT may work better in imaging patients with soft tissue sarcomas.
Inclusion: Patients >= 18 years of age; Patients diagnosed with any stage of soft tissue sarcomas candidates for systemic therapies; Patients with one standard of care PET/CT scan up to 30 days before enrollment at the Ohio State University facilities.
Exclusion: Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.); Hypersensitivity to somatostatin or similar peptides; Patients with acute infections; Somatostatin long-acting analog in the past 6 months; Patients who are pregnant or lactating; Patients who are currently incarcerated; Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the dPET/CT scanner due to body mass index (BMI).